BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19877121)

  • 1. IDH1 and IDH2 hotspot mutations are not found in canine glioma.
    Reitman ZJ; Olby NJ; Mariani CL; Thomas R; Breen M; Bigner DD; McLendon RE; Yan H
    Int J Cancer; 2010 Jul; 127(1):245-6. PubMed ID: 19877121
    [No Abstract]   [Full Text] [Related]  

  • 2. Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
    Fraser AR; Bacci B; le Chevoir MA; Long SN
    J Comp Pathol; 2018 Nov; 165():33-39. PubMed ID: 30502793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes.
    Kawakami S; Ochiai K; Azakami D; Kato Y; Michishita M; Morimatsu M; Ishiguro-Oonuma T; Onozawa E; Watanabe M; Omi T
    Vet Res Commun; 2018 Mar; 42(1):49-56. PubMed ID: 29285579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 and IDH2 mutations in gliomas.
    Ducray F; Marie Y; Sanson M
    N Engl J Med; 2009 May; 360(21):2248-9; author reply 2249. PubMed ID: 19469031
    [No Abstract]   [Full Text] [Related]  

  • 5. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 and IDH2 mutations in gliomas.
    De Carli E; Wang X; Puget S
    N Engl J Med; 2009 May; 360(21):2248; author reply 2249. PubMed ID: 19458374
    [No Abstract]   [Full Text] [Related]  

  • 7. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation.
    Kawakami S; Ochiai K; Kato Y; Michishita M; Hirama H; Obara R; Azakami D; Watanabe M; Omi T
    J Vet Med Sci; 2018 Jan; 80(1):85-91. PubMed ID: 29162772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy.
    Fu Y; Huang R; Zheng Y; Zhang Z; Liang A
    Biochem Biophys Res Commun; 2011 Jul; 410(2):218-23. PubMed ID: 21641335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
    Lu VM; McDonald KL
    CNS Oncol; 2018 Jan; 7(1):41-50. PubMed ID: 29303363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
    Singh A; Gurav M; Dhanavade S; Shetty O; Epari S
    Neuropathology; 2017 Dec; 37(6):582-585. PubMed ID: 28782849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioma-derived mutations in IDH: from mechanism to potential therapy.
    Fu Y; Huang R; Du J; Yang R; An N; Liang A
    Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IDH1, IDH2].
    Suzuki H; Aoki K; Ohka F; Natsume A
    Nihon Rinsho; 2016 Sep; 74 Suppl 7():117-121. PubMed ID: 30634740
    [No Abstract]   [Full Text] [Related]  

  • 15. Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance.
    Fu Y; Zheng S; Zheng Y; Huang R; An N; Liang A; Hu C
    Int J Biochem Cell Biol; 2012 May; 44(5):770-5. PubMed ID: 22309944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioma IDH1 mutation patterns off the beaten track.
    Pusch S; Sahm F; Meyer J; Mittelbronn M; Hartmann C; von Deimling A
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):428-30. PubMed ID: 20874727
    [No Abstract]   [Full Text] [Related]  

  • 17. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
    Weller M; Wick W; von Deimling A
    Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?
    Labussiere M; Sanson M; Idbaih A; Delattre JY
    Oncologist; 2010; 15(2):196-9. PubMed ID: 20133500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities?
    Mustafa DA; Swagemakers SM; Buise L; van der Spek PJ; Kros JM
    Acta Neuropathol Commun; 2014 Jan; 2():6. PubMed ID: 24405933
    [No Abstract]   [Full Text] [Related]  

  • 20. IDH Mutation Analysis in Glioma Patients by CADMA Compared with SNaPshot Assay and two Immunohistochemical Methods.
    Urbanovska I; Megova MH; Dwight Z; Kalita O; Uvirova M; Simova J; Tuckova L; Buzrla P; Palecek T; Hajduch M; Dvorackova J; Drabek J
    Pathol Oncol Res; 2019 Jul; 25(3):971-978. PubMed ID: 29556922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.